Our findings suggest that α1(IV)NC1 and its N- and C- terminal domains α1S1(IV)NC1 and α1S2(IV)NC1 may also be effective in inhibition of tumor angiogenesis by activating caspase-3 in new blood vessels. Here, CASP3 is linked to neoplasm.